Citation Impact
Citing Papers
Evolution of the Cancer Stem Cell Model
2014 Standout
Phase II randomized, double-blind, placebo-controlled study of whole-brain irradiation with concomitant chloroquine for brain metastases
2013
Pilot Study of a Specific Dietary Supplement inTumor-Bearing Mice and in Stage IIIB and IV Non-Small Cell Lung Cancer Patients
2001
Romidepsin: a novel histone deacetylase inhibitor for cancer
2011
Association of a Leukemic Stem Cell Gene Expression Signature With Clinical Outcomes in Acute Myeloid Leukemia
2010
The Role of Phenolic Compounds in the Fight against Cancer – A Review
2013
Guidelines on the use of therapeutic apheresis in clinical practice—Evidence‐based approach from the apheresis applications committee of the American Society for Apheresis
2010
Natural products: An evolving role in future drug discovery
2011 Standout
Niemann-Pick disease type C
2010 Standout
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
Nutrition and physical activity guidelines for cancer survivors
2012 Standout
Cancer Epigenetics: From Mechanism to Therapy
2012 Standout
WHO-EORTC classification for cutaneous lymphomas
2005 Standout
Sézary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC)
2010
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
2010 Standout
Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Français de Pneumo-Cancérologie (GFPC) Protocol 95-1
2001
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents
2010
Cell-free nucleic acids as biomarkers in cancer patients
2011 Standout
Treatment of brain metastases in patients with non-small cell lung cancer (NSCLC) by stereotactic linac-based radiosurgery: prognostic factors
2002
Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases
2014
European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2017
2017
Light‐Controlled Histone Deacetylase (HDAC) Inhibitors: Towards Photopharmacological Chemotherapy
2015 StandoutNobel
Microtubule-binding agents: a dynamic field of cancer therapeutics
2010 Standout
Stereotactic radiosurgery for patients with nonsmall cell lung carcinoma metastatic to the brain
1997
Targeting autophagy in cancer
2017 Standout
Indoles as therapeutics of interest in medicinal chemistry: Bird's eye view
2017 Standout
Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges
2009
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
Extracorporeal photochemotherapy in mycosis fungoides
2017
The prognostic landscape of genes and infiltrating immune cells across human cancers
2015 Standout
Guidelines on the use of therapeutic apheresis in clinical practice—Evidence‐based approach from the apheresis applications committee of the American society for apheresis
2007
Panobinostat in lymphoid and myeloid malignancies
2013
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue
2019 Standout
SuFEx Click Chemistry Enabled Late-Stage Drug Functionalization
2018 StandoutNobel
Primary Cutaneous B-Cell Lymphoma Treated With Radiotherapy: A Comparison of the European Organization for Research and Treatment of Cancer and the WHO Classification Systems
2004
Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
2009 Standout
The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy
2009
Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases
2012
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice—Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Sixth Special Issue
2013
Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas
2010
Natural product and natural product derived drugs in clinical trials
2014 Standout
Histone Deacetylase Inhibitors in Cancer Therapy
2009
Histone deacetylase inhibitor treatment dramatically reduces cholesterol accumulation in Niemann-Pick type C1 mutant human fibroblasts
2011
Panobinostat (LBH589): A Potent Pan-Deacetylase Inhibitor with Promising Activity Against Hematologic and Solid Tumors
2009
CutaneousT ‐cell lymphoma: 2016 update on diagnosis, risk‐stratification, and management
2015
A retrospective comparative outcome analysis following systemic therapy in M ycosis fungoides and S ezary syndrome
2016
How I treat mycosis fungoides and Sézary syndrome
2016
Hematological Problems in Pediatric Intensive Care
2013 Standout
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
2003 Standout
Systemic therapy for cutaneous T-cell lymphoma: who, when, what, and why?
2016
Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design
2011 Standout
The role of extracorporeal photopheresis in the management of cutaneous T‐cell lymphoma, graft‐versus‐host disease and organ transplant rejection: a consensus statement update from the UK Photopheresis Society
2017
Works of Gail Ryan being referenced
Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma
2008
A randomised phase III study of palliative radiation with concomitant carboplatin for brain metastases from non-small cell carcinoma of the lung
2004
Cutaneous lymphomas: which pathological classification?
2002
Treatment of brain metastases from primary lung cancer
1995
Extracorporeal photopheresis for the treatment of Sézary syndrome using a novel treatment protocol
2008
Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy
2014
Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation
2008